PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

Diabetes 40

Diabetes Biosimilars 40

PharmaShots

JUNE 16, 2023

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

Diabetes 40

Diabetes Labelling 40

PharmaShots

JUNE 9, 2023

Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies Date: June 09, 2023 | Tags: Quell Therapeutics, AstraZeneca, Engineered Treg Cell Therapies, Type 1 Diabetes, Inflammatory Bowel Disease, Biotech, Treg cell engineering modules Astellas and the (..)

Biosimilars 40

Biosimilars Diabetes 40

PharmaShots

MAY 26, 2023

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer Date: May 26, 2023 | Tags: Takeda, HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, Regulatory, Priority Review, US, FDA Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19 Date: (..)

Biosimilars 40

Biosimilars 40

PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

Chemotherapy 40

Chemotherapy Biosimilars Immunity Immunization 40

PharmaShots

APRIL 21, 2023

Oblato Reports the First Patient Enrolment of OKN-007 in the P-I Clinical Trial for Recurrent High-Grade Glioma Date: Apr 21, 2023 | Tags: Oblato, OKN-007, Recurrent High-Grade Glioma, Regulatory, Henry Ford Health System CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer Date: (..)

Labelling 40

Labelling 40

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

Diabetes 40

Diabetes Biosimilars 40

PharmaShots

MARCH 31, 2023

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer Date: Mar 31, 2023 | Tags: PDS Biotech, PDS0101, Keytruda, pembrolizumab, Head, Neck Cancer, Clinical Trial, P-III, VERSATILE-003 Trial Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular (..)

Diabetes 40

Diabetes 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

Biosimilars 40

Biosimilars 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

Biosimilars 40

Biosimilars 40

Pharmaceutical Technology

SEPTEMBER 30, 2022

Skysona is indicated as a one-time gene therapy to slow the progression of cerebral adrenoleukodystrophy (CALD), a rare paediatric neurodegenerative disease in boys aged 4–17 years diagnosed with early-stage CALD. These approvals represent crucial milestones for bluebird bio, the gene therapy field, and patients with rare genetic diseases.

115

115

pharmaphorum

NOVEMBER 19, 2021

It is recommended as a treatment for people aged two months and older with types 1, 2 and 3 SMA, as well as some people with the condition before they start showing symptoms. million price tag make it is the most expensive treatment ever approved for NHS funding.

97

97

pharmaphorum

JUNE 12, 2022

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 Haematopoietic stem cell transplantation (HSCT) offers a chance of a cure, but is only possible when a donor with a matching human leukocyte antigen (HLA) signature, within the correct age range, is available.

59

59

pharmaphorum

APRIL 14, 2022

million price tag. Patients with the most severe form of inherited disorder develop life-threatening anaemia from the age of around four to six months and have to undergo monthly blood transfusions as well as additional treatment to prevent complications, such as chelation drugs to remove excess iron from the body.

64

64

Pharmaceutical Technology

DECEMBER 5, 2022

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. This is closely followed by CB2 receptors in second place. This is followed by epilepsy at 8% of the pipeline and multiple sclerosis at 7% of the pipeline.

Controlled Substances 98

Controlled Substances Compounding Immunity Immunization 98

pharmaphorum

NOVEMBER 19, 2020

Lucentis (ranibizumab) was first FDA approved in 2006 for wet age-related macular degeneration (wet AMD) and has picked up approvals in related eye conditions ever since, although its patent expired in June.

Biosimilars 64

Biosimilars Labelling 64

PharmaState Academy

JUNE 24, 2023

That’s the power of sound in a tag line. Consider factors like age, demographics, and cultural background. In the omnichannel age, creating a consistent ‘Voice of Your Brand’ across all touchpoints is crucial. The latter doesn’t even make dictionary sense. Yet Liril has left an indelible mark.

Communication 52

Communication 52

pharmaphorum

SEPTEMBER 15, 2020

“Digitally native brands are typically agile businesses from the ground up, and agility and flexibility are part of their core makeup,” says Joe Holmes, vice president, marketing services, US at Tag. Jeremy Richter, Tag. Joe began his life at Tag in the UK, bringing efficiencies to his clients, working across all conceivable channels.

Communication 114

Communication Documentation Labelling Vaccines 114

pharmaphorum

JANUARY 21, 2022

Balancing the incentivisation of innovation against affordable access to revolutionary new medicines is an age-old conundrum in the biopharmaceutical industry. In recent years, revolutionary medicines have come with price tags to match, but this is simply a symptom of our current model.

Vaccines 52

Vaccines 52

PharmD Live

JANUARY 25, 2022

A PharmD dedicated to knowing approved medications and understanding the medical situations in which they are applied is critical to caring for and reducing risk to the aged and vulnerable Medicare patient population. The aging population sees more specialists. 88% report that their EHR produces clinical benefits for the practice.

Adverse Reactions 52

Adverse Reactions Doctor of Pharmacy Diabetes Communication 52

pharmaphorum

JUNE 2, 2021

It added that there is evidence that Evrysdi is a life-extending treatment for SMA type 1, the most serious from of the disease that generally leads to death before the age of 2 if untreated, and as an oral drug is an alternative for people who cannot have the other SMA treatment options.

Documentation 52

Documentation Communication 52

PharmD Live

DECEMBER 21, 2021

With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag. For people with diabetes, the ADA makes new recommendations and strategies for classes of care, age and type, strategies to prevent or delay onset of T2 diabetes. See it here.

Diabetes 52

Diabetes Hospitals 52

RX Note

NOVEMBER 13, 2023

total size, age and income distribution, buying power, occupation trends) Prescriptions will be in higher demands in areas where there is an older demographic. Name tag with the word "Pharmacist". Demand - Wants backed by purchasing power. Competitive characteristics (e.g. Minimum 40 hours/week with pharmacist.

Community Pharmacies 52

Community Pharmacies Health and Personal Care Stores Documentation Independent Pharmacies 52

RX Note

MAY 1, 2023

However, is it really that easy to attain financial stability, especially at young age? However, we should not forget that every luxury or lifestyle choice has a price tag attached to it. Expenses While our grandparents may have prioritized saving for a rainy day, many young people today believe in living in the moment.

40

40

Fuld & Company Blog

MARCH 27, 2023

However, there are still plenty of people who are willing to pay out of pocket for semaglutide, despite the high price tag and, hence, could opt to pay for either Wegovy or Ozempic. With trials showing potential weight loss of 10% to 15% , for many, the price tag of $1,500 per month is well worth it. It has gone mainstream.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

pharmaphorum

AUGUST 28, 2020

But the advent of COVID-19 is proving to be something of a coming of age for digital epidemiology, which has been putting data from disparate sources to global use for the last 15 years. We are ingesting hundreds of thousands of pieces of information daily and we tag that information across locations, disease types, species, and case counts.

Hospitals 65

Hospitals 65

epicur

MAY 16, 2024

So, I first became interested in veterinary medicine at a young age. Ironically, last year, during the ACVO/Epicur National Service Animal Eye Exam Event , one of the participants tagged my account in a post, and that sparked me to start posting on the account. She had horses, and my mom was a big horseback rider.

Compounding 52

Compounding Hospitals 52

PharmaShots

MARCH 10, 2023

Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes Date: Mar 10, 2023 | Tags: Vertex, VX-264, Type 1 Diabetes, Regulatory, US, FDA, IND Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies Date: Mar 10, 2023 | Tags: Alnylam, Medison Pharma, RNAi Therapies, Onpattro, patisiran, (..)

Diabetes 40

Diabetes Biosimilars Vaccines 40

FDA Law Blog: Biosimilars

JUNE 27, 2023

The honor was bestowed on only 183 attorneys, which is awarded to “top attorneys under 40 whose legal accomplishments belie their age.” In addition to Mr. Karst, ten other HP&M Directors were tagged as “Recommended” by WWL: Life Sciences 2023: Ricardo Carvajal Robert A. Valentine , as a 2023 Rising Star. Dormer Jeffrey N.

Drug Development 81

Drug Development Pharmaceutical Manufacturing 81

pharmaphorum

AUGUST 10, 2020

While this is not cheap by anybody’s reckoning, Roche hopes that the less intimidating price tag, plus the patient-friendly oral administration method will give it a competitive edge. The FDA approved Evrysdi for the treatment of spinal muscular atrophy (SMA) in adults and children two months of age and older.

Specialty Pharmacies 59

Specialty Pharmacies 59

pharmaphorum

FEBRUARY 16, 2021

But haematopoietic stem cell transplantation is only possible when a donor with a matching human leukocyte antigen signature, within the correct age range, is available. million in Europe. NICE said that data came from a small sample of patients and is using its standard discount rate of 3.5%

72

72

pharmaphorum

DECEMBER 7, 2021

That finding could provide some comfort to Biogen and Eisai, whose recently-approved amyloid-targeting drug Aduhelm (aducanumab) is struggling to gain traction in the market on the back of unconvincing efficacy data, safety concerns and a high price tag.

Compounding 52

Compounding Diabetes 52

European Pharmaceutical Review

DECEMBER 27, 2023

Other examples include the absence of age requirement/limitation for CAR T-cell therapy and that chemo sensitivity is not mandatory for CAR treatment. This is in addition to its considerable price tag. 6-8 Clinical recommendations also change. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. 2013;368(16):1509–18.

Adverse Reactions 83

Adverse Reactions Immunity Immunization Medical Schools 83

RX Note

FEBRUARY 9, 2024

Age-related macular degeneration (AMD) 年龄相关性黄斑变性 (也称老年黄斑病变) - A disease that affects a person's central vision. Kawasaki Disease 川崎 - An acute febrile illness of unknown cause that primarily affects children younger than 5 years of age. Skin tags 皮赘 - Small, soft, skin-coloured growths on your skin. of a disease).

Immunity 40

Immunity Immunization Diabetes Communication 40

Pharma Marketing Network

JUNE 8, 2020

Unfortunately, having had ten friends my age or younger die by the time I was 40 gave me a very unique look into health care and some of the devastating impacts of it. Don (PMN): Yeah sure, it affects you personally in a big way, 10 people, that’s pretty incredible. Dave (HR): Oh, no, I think the Specialty Pharmacy.

Health and Personal Care Stores 40

Health and Personal Care Stores Mayo Clinic Hospitals Specialty Pharmacies 40